Somite AI Company Profile

Background

Somite AI, established in October 2023, is a venture-backed company dedicated to revolutionizing stem cell biology through artificial intelligence (AI). The company's mission is to transform the lives of millions by leveraging AI to produce human tissue for cell-based therapies, addressing diseases such as diabetes, obesity, and muscular dystrophies. Somite AI aims to become the "OpenAI of stem cell biology," developing AI foundation models to produce human tissue for cell therapies at scale.

Key Strategic Focus

Somite AI's strategic focus centers on developing a digital twin of the embryo—a computational model that simulates real embryo development and behavior to guide decision-making. This model is constructed from data-rich sources, including single-cell RNA sequencing (scRNA-Seq), single-cell ATAC sequencing (scATAC-seq), and gene expression databases. By leveraging AI, Somite AI aims to rapidly identify novel protocols for generating new cell types, discover new regulators of cell differentiation, and carry out rapid protocol optimization cycles. The company's primary markets include cell replacement therapies targeting conditions such as metabolic diseases, Duchenne muscular dystrophy (DMD), joint and cartilage injuries, connective tissue syndromes, and severe burns.

Financials and Funding

Since its inception, Somite AI has successfully raised over $10 million in funding. In April 2024, the company secured $5.3 million in pre-seed funding led by TechAviv, with participation from Next Coast Ventures, Trust Ventures, Texas Venture Partners, and Lerer Hippeau. In September 2024, Somite AI announced a pre-seed extension round, raising an additional $4.8 million from Astellas Venture Management and Montage Ventures. The capital is intended to further develop the proprietary AlphaStem AI platform, establish Somite labs, and advance the company's therapeutic assets into clinical trials.

Pipeline Development

Somite AI's pipeline includes:

SMT-M01: A flagship program targeting Duchenne muscular dystrophy (DMD). In September 2024, Somite AI announced a collaboration with OmniaBio Inc. to advance this program, with plans to enter Phase 1/2 clinical trials within 18-24 months.

SMT-B01: A program focused on metabolic disorders, including diabetes and obesity. This program is in the preclinical development stage.

Technological Platform and Innovation

Somite AI's proprietary technological platform, AlphaStem, is designed to produce human tissue for cell therapies at scale. The platform utilizes a digital twin of the embryo, constructed from comprehensive datasets such as scRNA-Seq and scATAC-seq. This approach enables the company to:

Rapidly identify novel protocols for generating new cell types.

Discover new regulators of cell differentiation.

Optimize production protocols efficiently.

By integrating AI with extensive biological data, Somite AI aims to overcome existing challenges in cell therapy, such as efficiency, scalability, and robustness.

Leadership Team

Somite AI's leadership comprises experienced professionals with diverse backgrounds:

Micha Breakstone, Ph.D.: Co-Founder & CEO. A repeat AI entrepreneur, previously co-founded Chorus.ai, acquired for $575 million.

Jonathan Rosenfeld, Ph.D.: Co-Founder & CTO. Former Head of the Fundamental AI group at MIT FutureTech.

Carl Morris, Ph.D.: Chief Scientific Officer.

Kristy Brown, Ph.D.: SVP of Translational Development.

Scientific Co-Founders include:

Olivier Pourquie, Ph.D.: Professor of Genetics and Pathology at Harvard Medical School and Brigham and Women's Hospital.

Allon Klein, Ph.D.: Associate Professor of Systems Biology at Harvard Medical School.

Cliff Tabin, Ph.D.: Chair of the Department of Genetics at Harvard Medical School.

Jay Shendure, M.D., Ph.D.: HHMI Investigator and Professor of Genome Sciences at the University of Washington.

Leadership Changes

In 2024, Somite AI appointed Shai Kivity as Vice President of Operations & Strategy. Kivity brings a strong background in operational and strategic management, enhancing the company's capabilities as it scales its operations.

Competitor Profile

Market Insights and Dynamics

The global cell therapy market is experiencing significant growth, driven by advancements in regenerative medicine and increasing demand for personalized treatments. The market is projected to reach substantial valuations, with a focus on developing therapies for chronic diseases and rare genetic disorders.

Competitor Analysis

Key competitors in the AI-driven cell therapy space include:

bit.bio: A biotechnology company specializing in the production of human cells for research and therapy using synthetic biology approaches.

Myogenica: A venture-backed company focusing on developing gene therapies for muscle-related diseases.

These companies are also leveraging advanced technologies to address challenges in cell therapy, such as scalability and efficiency.

Strategic Collaborations and Partnerships

In September 2024, Somite AI announced a collaboration with OmniaBio Inc., a global cell and gene therapy contract development and manufacturing organization (CDMO). This partnership aims to advance Somite's SMT-M01 program for DMD by leveraging OmniaBio's expertise in induced pluripotent stem cell (iPSC) technology, process optimization, and regulatory compliance.

Operational Insights

Somite AI's integration of AI with stem cell biology positions the company uniquely in the market. By developing a digital twin of the embryo, Somite AI addresses existing challenges in cell therapy production, such as efficiency, scalability, and robustness. The company's strategic collaborations and strong leadership team further enhance its competitive advantage.

Strategic Opportunities and Future Directions

Somite AI plans to continue developing its AlphaStem platform and advance its therapeutic programs into clinical trials. The company aims to expand its pipeline to address a broader range of diseases involving cell loss or deficiency. By leveraging AI and big data, Somite AI seeks to accelerate the development of cell replacement therapies and establish itself as a leader in the field.